Hodgkin Lymphoma News and Research RSS Feed - Hodgkin Lymphoma News and Research

Autologous stem cell transplant safe, effective for HIV-associated lymphoma patients

Autologous stem cell transplant safe, effective for HIV-associated lymphoma patients

New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents. [More]
Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in the most aggressive large B-cell lymphomas (DLBCL). By reducing NFκB signaling, miR-181a controls tumor cell proliferation and survival and could be the target of novel therapies. The study was published in the journal Blood. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies. [More]
Higher body weight, taller stature during adolescence increase NHL risk

Higher body weight, taller stature during adolescence increase NHL risk

A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's Lymphoma (NHL), a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. [More]
Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found. [More]
African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers. [More]
New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective. [More]
New study examines single 'transformer' proteins involved in cancer

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures. [More]
Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer. [More]
Many European hospitals fail to routinely test people at risk of HIV infection

Many European hospitals fail to routinely test people at risk of HIV infection

A new study reveals that many European hospitals fail to routinely test people who may be at risk of an HIV-infection. If tests were more widely offered in the healthcare system, fewer HIV-patients would go unnoticed, especially in Northern Europe. [More]
Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients. [More]
Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. [More]
Advertisement
Advertisement